Ellis Andrea 4

What Happened

• Andrea Ellis, a director of BridgeBio Pharma (BBIO), exercised 64,921 stock options and sold the resulting 64,921 shares on March 4, 2026. The exercise recorded a cost basis of $8.45 per share (total ~$548,582), and the shares were sold in the open market for an average price of $64.87 per share (total proceeds ~$4,211,302). The transactions were reported on a Form 4 filed March 6, 2026.

Key Details

• Transaction dates: March 4, 2026 (reported March 6, 2026); filing appears timely (within two business days).
• Exercise: 64,921 shares exercised at $8.45/share (code M), total cash paid ~$548,582.
• Sale: 64,921 shares sold in the open market at a weighted average price reported as $64.87/share (range $64.255–$65.21), total proceeds ~$4,211,302.
• Additional entry: a derivative disposition reported at $0.00 reflecting conversion of the option into shares.
• Shares owned after the transaction: Not specified in the filing.
• Footnotes: (F1) Sale occurred under a Rule 10b5-1 trading plan adopted Dec 3, 2025; (F2) sale price range provided and detailed price breakdown available on request; (F3) option vesting occurred in three annual installments through June 22, 2025 (so options were vested).

Context

• This is effectively a same‑day exercise and sale (often called a cashless exercise): options were converted to shares and those shares were sold the same day under a pre-established 10b5‑1 plan. Such pre-arranged plans are commonly used to avoid questions about timing and insider knowledge and are considered routine rather than an explicit signal of company outlook.